Mimi Lee, M.D., Ph.D.

Mimi Lee joined ARPA-H in July 2024. Lee is a physician-scientist with deep experience in academia, clinical practice, and innovative genetic medicines development in biotech and pharma. She has served as the Global Medical Lead for BioMarin’s inaugural gene therapy program in hemophilia A and as the Translational Program Head at Novartis, leading multidisciplinary asset teams for rare neurodegenerative genetic diseases. Most recently, Lee led efforts to lay a strategic foundation for Samsung’s initial foray into novel regenerative medicines development. 

Lee trained in neurological surgery at the Washington University School of Medicine and in anesthesiology and perioperative care at the University of California San Francisco where she also served as Assistant Professor. Her M.D./Ph.D. was funded by the Medical Scientist Training Program from the Albert Einstein College of Medicine. Her passion is co-creating with cross-functional, multi-disciplinary experts centrally aligned with the mission of bringing groundbreaking technologies to patients in need safely, efficiently and ethically.